08/07/2018

Recent Oncology Related Drug News

TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy

TAILORx, the largest trial ever conducted in early stage breast cancer was the #1 abstract at the plenary session at ASCO in June. The full trial results were also released in the NEJM at the same time. Many breast cancer experts have commented on the “practice changing” data.  READ MORE in ASCO Daily News CLICK HERE

FDA Discontinues Iclusig® REMS Program

(ASCO in Action) July 31, 2018 - ASCO has been notified that Takeda Oncology was recently advised by the U.S. Food and Drug Administration (FDA) that the REMS (Risk Evaluation and Mitigation Strategy) communication plan for ICLUSIG® (ponatinib) is no longer required.  READ ARTICLE

Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA® (lenvatinib) in Combination with KEYTRUDA® (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma

(Merck) July 31, 2018 - Eisai Co., Ltd. and Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for LENVIMA® (lenvatinib), the orally available kinase inhibitor discovered by Eisai, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the potential treatment of patients with advanced and/or metastatic non-microsatellite instability high (MSI-H)/proficient mismatch repair (pMMR) endometrial carcinoma (EC) who have progressed following at least one prior systemic therapy.  Read Corporate Press Release

Celgene Bows To White House Pressure After Raising Prices For Cancer Drug

(Washington Examiner) July 26, 2018 - After raising the price of its marquee cancer drug, Celgene said Thursday it doesn't plan further increases this year as the White House presses pharmaceutical companies to lower treatment costs. READ ARTICLE